PPARG and prostate carcinoma: For instance, treatment with the PPARγ agonist pioglitazone has been shown to reduce tumor growth in a metastatic PC3 prostate cancer xenograft model, accompanied by increased phosphorylation of AMPKα and decreased phosphorylation of mTOR.